An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
A son of glembatumumab vedotin has just started its phase 1 study.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
After setbacks, cema-cel might have a path to approval in lymphoma.
The group impresses in ovarian and endometrial cancers.
